Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

William Blum, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Sebastian Schwind, MD, Yao Jiang, Jiang Wang, Mitch Phelps, PhD, Susan Geyer, PhD, Steven M. Devine, MD, Kathy Walsh, MD, Sumithira Vasu, MBBS, John P. Curfman, Larry Schaaf, PhD, Celia Garr, RN, Cheryl Kefauver, RN, John C. Byrd, MD, Michael R. Grever, MD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2012) 120 (21): 2619.

https://doi.org/10.1182/blood.V120.21.2619.2619

Published: 2012

Journal Articles

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blood (2012) 119 (25): 6025–6031.

https://doi.org/10.1182/blood-2012-03-413898

Published: 2012

Includes: Supplemental data

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Todd A. Fehniger, John C. Byrd, Guido Marcucci, Camille N. Abboud, Cheryl Kefauver, Jacqueline E. Payton, Ravi Vij, William Blum

Blood (2009) 113 (5): 1002–1005.

https://doi.org/10.1182/blood-2008-04-152678

Published: 2009

Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2008) 112 (11): 2957.

https://doi.org/10.1182/blood.V112.11.2957.2957

Published: 2008

Journal Articles

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Leslie A. Andritsos, MD, Amy J. Johnson, Ph.D., William Blum, M.D., Cheryl Kefauver, R.N., Farrukh Awan, M.D., Lisa L. Smith, Rosa Lapalombella, Da-Sheng Wang, Robert D. Knight, Ching-Shih Chen, Ph.D., John C. Byrd, M.D.

Blood (2007) 110 (11): 4727.

https://doi.org/10.1182/blood.V110.11.4727.4727

Published: 2007

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD

Blood (2006) 108 (11): 4578.

https://doi.org/10.1182/blood.V108.11.4578.4578

Published: 2006

Journal Articles

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

William Blum, MD, Rebecca Bruner-Klisovic, MD, Shujun Liu, PhD, John C. Byrd, MD, Zhongfa Liu, PhD, Kenneth K. Chan, PhD, Cheryl Kefauver, R.N., Lenguyen Huynh, Michael R. Grever, MD, Guido Marcucci, MD

Blood (2005) 106 (11): 1861.

https://doi.org/10.1182/blood.V106.11.1861.1861

Published: 2005

Journal Articles

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

William Blum, M.D., Kristie A. Blum, M.D., Cheryl Kefauver, R.N., Mollie Moran, C.R.N.P., Kenneth Chan, Ph.D., John C. Byrd, M.D., Spero Cataland, M.D., Michael R. Grever, M.D., Guido Marcucci, M.D.

Blood (2004) 104 (11): 4528.

https://doi.org/10.1182/blood.V104.11.4528.4528

Published: 2004

NARROW

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only